ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: A randomized phase 2 study

Paolo Strati, Michelle A. Fanale, Yasuhiro Oki, Francesco Turturro, Luis E. Fayad, Nancy L. Bartlett, Douglas E. Gladstone, Yvette L. Kasamon, Carol S. Portlock, Wyndham H. Wilson, Andre Goy, Anas Younes, Hun Ju Lee

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: A randomized phase 2 study'. Together they form a unique fingerprint.